Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company, is making strides in the field of oncology through the use of artificial intelligence (AI) and machine learning. The company’s proprietary RADR(R) platform, which integrates over 200 billion oncology-specific data points, is at the forefront of this innovation. This technology is not only redefining the process of drug development but also significantly reducing the time and cost associated with bringing new therapies to market.
The RADR(R) platform supports Lantern Pharma’s pipeline of precision cancer therapies, with three lead drug candidates currently in clinical development. These candidates target major oncology markets, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and non-Hodgkin’s lymphoma (NHL). Additionally, through Starlight Therapeutics, Lantern is extending its research into brain and central nervous system (CNS) cancers, including pediatric indications that have been granted orphan and rare disease designations by the FDA.
Lantern Pharma’s innovative approach has garnered multiple FDA designations, such as Fast Track, Orphan Drug, and Rare Pediatric Disease status, across its portfolio. These designations not only underscore the potential of Lantern’s therapies to address unmet medical needs but also facilitate a smoother regulatory pathway for their development and approval.
The implications of Lantern Pharma’s work are profound. By leveraging AI to streamline the drug development process, the company is setting a new standard for efficiency and precision in oncology. This could lead to faster access to life-saving treatments for patients and a significant reduction in the costs associated with drug development. The success of Lantern Pharma’s approach could also inspire further integration of AI technologies in biopharmaceutical research, potentially transforming the industry at large.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development.